Form 4: ALX Oncology Director Acquires Stock Options

Chris H. Takimoto, a director at ALX Oncology Holdings Inc., acquired stock options for 40,400 shares of common stock.

Summary

• Chris H. Takimoto, a director of ALX Oncology Holdings Inc., has acquired options to purchase 40,400 shares of the company's common stock.
• The options have an exercise price of $1.65 per share.
• The options vest in 36 equal monthly installments starting on February 21, 2025.
• The options expire on January 20, 2035.
• The transaction was reported on January 23, 2025.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction, which is neither particularly positive nor negative. It is a standard part of corporate governance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotech sector, as a way to align their interests with those of shareholders.
• The vesting schedule of 36 months is also a typical vesting period for stock options.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, ALX Oncology, director, equity, ALXO